Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation.
about
Conduction abnormalities and ventricular arrhythmogenesis: The roles of sodium channels and gap junctionsIon Channels in the HeartGap junctionsAtrial fibrillation therapy now and in the future: drugs, biologicals, and ablationAtrial Electrophysiological Remodeling and Fibrillation in Heart FailureMaking better scar: Emerging approaches for modifying mechanical and electrical properties following infarction and ablationPulmonary venous structural remodeling in a canine model of chronic atrial dilation due to mitral regurgitationTransmural characteristics of atrial fibrillation in canine models of structural and electrical atrial remodeling assessed by simultaneous epicardial and endocardial mappingIncreased interstitial loading reduces the effect of microstructural variations in cardiac tissue.Recent advances in pharmacotherapy of atrial fibrillationThe role of gap junctions in stretch-induced atrial fibrillation.Atrial fibrosis and the mechanisms of atrial fibrillationCharacterization of gap junction remodeling in epicardial border zone of healing canine infarcts and electrophysiological effects of partial reversal by rotigaptideNovel pharmacological targets for the rhythm control management of atrial fibrillation.Drug therapy in atrial fibrillation management: where do we stand in 2010?New antiarrhythmic treatment of atrial fibrillation.Enhancement of ventricular gap-junction coupling by rotigaptide.Connexin diversity in the heart: insights from transgenic mouse models.Atrial-selective sodium channel block for the treatment of atrial fibrillation.Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics.Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure.New pharmacological strategies for the treatment of atrial fibrillationTargeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins.Animal models for atrial fibrillation: clinical insights and scientific opportunities.New developments in atrial antiarrhythmic drug therapy.Arrhythmias and vagus nerve stimulation.Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations.Atrial fibrillation-the final frontier.Novel molecular targets for atrial fibrillation therapy.Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation.Alternans in atria: Mechanisms and clinical relevance.Connexin Remodeling Contributes to Atrial Fibrillation.Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization.Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation.Genotype influence in responses to therapy for atrial fibrillation.Increased Susceptibility to Atrial Fibrillation Secondary to Atrial Fibrosis in Transgenic Goats Expressing Transforming Growth Factor-β1.Note on a possible proarrhythmic property of antiarrhythmic drugs aimed at improving gap-junction coupling.Protein kinase Cepsilon mediates salutary effects on electrical coupling induced by ischemic preconditioning.Very-Low-Density Lipoprotein of Metabolic Syndrome Modulates Gap Junctions and Slows Cardiac ConductionAdvances in the Pharmacologic Management of Atrial Fibrillation.
P2860
Q26769921-2E972176-B0F7-4712-BF42-84A59E875B97Q26829681-B572FCF8-2340-472A-A151-3FE85A61139BQ26850591-5DFBE3DA-D3BA-41CD-ACB1-1FDB9760F4B9Q26864767-38F777BD-D973-43CD-B772-8561D7DB4A6FQ28066307-157D194C-DFDF-48C9-A731-C96A69DF9F80Q30277999-C7D62E86-82AE-42A0-B22A-2220DB2E4007Q33327500-052EE911-2F89-4B6C-851B-0779C8CFA40CQ33746539-9B0353AA-3F85-4847-B5DC-8A4EFCA6B2ACQ33784411-262E8327-491F-4FCF-82B5-3B0709DE0CCAQ33874035-5D073692-4B44-4909-8806-8369C6017AC9Q34443546-8EF504BF-817F-435C-BEFA-3F48E0CA78E1Q34576855-E4FA2B70-33B2-4B3F-A8BF-C75AA84B2644Q35048220-C061F084-0293-4E44-9EA5-6F919957DC83Q35489060-F5A6369A-DADC-4949-A454-167CDDAA4E88Q36305013-632A110E-6BD4-434E-93E1-0DB2A179B424Q36867290-B063CAF6-44B7-443B-8A67-3DD7D4E882B7Q36952968-B3DB3F9C-B702-4182-A130-DA17081596C0Q36958996-64EBEF98-BD6D-49FC-B7F9-2F4878986634Q37494653-FF46FD54-F92E-44F1-B16D-CBE469F54E28Q37495775-9AD3B661-3C8A-4E58-A11D-F00E45C977DAQ37496298-FD793A64-90C3-45CE-9039-A7E349E7596AQ37554693-ABD7F9B3-7563-4DD9-80BD-3EF4C388620EQ37602866-BC4913DD-51BD-49F4-86E4-FBDBDA8182DEQ37624219-440AC7A8-080E-46E7-8EE4-9A66BEF5BCD7Q37697498-CDD5F443-7E22-4EDE-812D-9C5995A4EF90Q37766114-10A40F59-2713-47FB-B202-A89D9609E135Q37766393-D1822FE3-743B-4051-9287-43BD09D7DA48Q37799693-FBB8CFA8-F4EB-4F11-9352-47E04C6B2B03Q37998312-1B972B15-BADC-4D03-84E6-C0C0ECC723DEQ38435600-F916DBB0-4FE5-465D-AA8A-79AFCB517645Q38699661-2D71E3E7-012A-4A84-8EA3-F87DB220903AQ38790389-1EA42BDB-B9E1-4825-8967-3C57885CECC0Q38822819-B82C476E-1008-4783-9AA4-45B11C5E19E3Q38853630-9C70CD33-DB1C-425B-9DAC-E3ABFB8B249FQ38894994-73FF8E03-768E-4A3E-8B36-AE068149A068Q39571123-B39334EE-19C2-4350-9A4C-4AF58B142EA7Q40482937-8FEC3819-2F0E-4585-AA4B-ABA2EEBDEEADQ42110944-2A469CBA-1158-4EA4-9B71-B91CF946AB3BQ42362264-2DBB0486-F045-44A4-BA81-A98742ED9741Q42777572-CB5A9F77-DF53-4EBE-8B64-DA50988973F0
P2860
Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Effects of the gap junction mo ...... bility to atrial fibrillation.
@en
Effects of the gap junction modifier rotigaptide
@nl
type
label
Effects of the gap junction mo ...... bility to atrial fibrillation.
@en
Effects of the gap junction modifier rotigaptide
@nl
prefLabel
Effects of the gap junction mo ...... bility to atrial fibrillation.
@en
Effects of the gap junction modifier rotigaptide
@nl
P2093
P1433
P1476
Effects of the gap junction mo ...... bility to atrial fibrillation.
@en
P2093
Emily Wilson
Jeffrey E Olgin
Thomas H Everett
P304
P356
10.1161/CIRCULATIONAHA.105.606251
P407
P577
2006-07-03T00:00:00Z